GlassScriptPhysician profile
James D Harrover
NPI 1669489084
$14,886.34
in general payments reported to CMS, 2019-2025
53 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,153 · 2020: $2,187 · 2021: $2,752 · 2022: $2,046 · 2023: $2,218 · 2024: $1,791 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,729 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,728.91 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,425.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,757.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $963.20 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $869.65 | 2019-2025 | |
| Amgen INC. | $809.86 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $757.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $566.34 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $561.99 | 2019-2025 | Spravato |
| Lilly USA, LLC | $497.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $450.39 | 2021-2025 | |
| Abbott Laboratories | $424.36 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.61 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $382.86 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $300.52 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $273.08 | 2019-2023 | Dificid, Verquvo, Belsomra |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harrover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.